Literature DB >> 25532075

Prevalence of muscular dystrophies: a systematic literature review.

Alice Theadom1, Miriam Rodrigues, Richard Roxburgh, Shiavnthi Balalla, Chris Higgins, Rohit Bhattacharjee, Kelly Jones, Rita Krishnamurthi, Valery Feigin.   

Abstract

BACKGROUND: Determining the prevalence of neuromuscular disorders for the general population is important to identify the scope of burden on society and enable comparisons with other health conditions. This systematic review aims to identify and collate the findings of studies published between 1960 and 2013 on the prevalence of all types of muscular dystrophies.
SUMMARY: Relevant articles were identified through electronic database searches and manual searches of reference lists. There were 38 articles from across 19 countries that met the inclusion criteria. The total combined prevalence for all muscular dystrophies for studies classified as having a low risk of bias ranged between 19.8 and 25.1 per 100,000 person-years. Myotonic dystrophy (0.5-18.1 per 100,000), Duchenne muscular dystrophy (1.7-4.2) and facioscapulohumeral muscular dystrophy (3.2-4.6 per 100,000) were found to be the most common types of disorder. There was wide variation in study methodology, case ascertainment, and verification procedures and populations studied, all of which may contribute to the wide prevalence range, in addition to the likely variation in prevalence by country. Key Messages: Greater consistency in the conduct and reporting of neuroepidemiological studies is urgently needed to enable comparisons to be made between studies, countries, and over time.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2014        PMID: 25532075     DOI: 10.1159/000369343

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  65 in total

1.  Allele length of the DMPK CTG repeat is a predictor of progressive myotonic dystrophy type 1 phenotypes.

Authors:  Gayle Overend; Cécilia Légaré; Jean Mathieu; Luigi Bouchard; Cynthia Gagnon; Darren G Monckton
Journal:  Hum Mol Genet       Date:  2019-07-01       Impact factor: 6.150

2.  Cardiac manifestations in Emery-Dreifuss muscular dystrophy.

Authors:  Whitney Faiella; Ricardo Bessoudo
Journal:  CMAJ       Date:  2018-12-03       Impact factor: 8.262

Review 3.  Myositis Mimics.

Authors:  E Harlan Michelle; Andrew L Mammen
Journal:  Curr Rheumatol Rep       Date:  2015-10       Impact factor: 4.592

4.  Myotonic dystrophy type 1.

Authors:  Cam-Tu Emilie Nguyen; Craig Campbell
Journal:  CMAJ       Date:  2016-06-06       Impact factor: 8.262

5.  Parental Reflections on the Diagnostic Process for Duchenne Muscular Dystrophy: A Qualitative Study.

Authors:  Roxanna M Bendixen; Amy Houtrow
Journal:  J Pediatr Health Care       Date:  2016-10-12       Impact factor: 1.812

Review 6.  Myotonic dystrophy: disease repeat range, penetrance, age of onset, and relationship between repeat size and phenotypes.

Authors:  Kevin Yum; Eric T Wang; Auinash Kalsotra
Journal:  Curr Opin Genet Dev       Date:  2017-02-14       Impact factor: 5.578

7.  Nanotopography-responsive myotube alignment and orientation as a sensitive phenotypic biomarker for Duchenne Muscular Dystrophy.

Authors:  Bin Xu; Alessandro Magli; Yoska Anugrah; Steven J Koester; Rita C R Perlingeiro; Wei Shen
Journal:  Biomaterials       Date:  2018-08-21       Impact factor: 12.479

8.  A Nationwide, Population-Based Prevalence Study of Genetic Muscle Disorders.

Authors:  Alice Theadom; Miriam Rodrigues; Gemma Poke; Gina O'Grady; Donald Love; Graeme Hammond-Tooke; Priya Parmar; Ronelle Baker; Valery Feigin; Kelly Jones; Braden Te Ao; Anna Ranta; Richard Roxburgh
Journal:  Neuroepidemiology       Date:  2019-01-18       Impact factor: 3.282

9.  Chick embryonic cells as a source for generating in vitro model of muscle cell dystrophy.

Authors:  Verma Urja; Kashmira Khaire; Suresh Balakrishnan; Gowri Kumari Uggini
Journal:  In Vitro Cell Dev Biol Anim       Date:  2018-10-09       Impact factor: 2.416

10.  Cardiac Disease Burden and Risk of Mortality in Hospitalized Muscular Dystrophy Patients.

Authors:  Ann R Punnoose; Jonathan R Kaltman; William Pastor; Robert McCarter; Jianping He; Christopher F Spurney
Journal:  Pediatr Cardiol       Date:  2016-06-17       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.